Loading...
Loading...
Deutsche Bank maintains its Buy rating on Gilead Sciences
GILD and raises its price target to $66 from $53 a share as it believes shares on increased confidence in HCV.
Deutsche Bank says, "We see Gilead as one of our top picks in large cap biotech, with above-average growth opportunities (‘12-‘18 revenue CAGR of 22%)and a series of HCV & HIV catalysts in 2012. We believe the street is underestimating the market oppy for ‘7977 in HCV as well as the ability of Gilead to take majority new HIV patient market share with its QUAD franchise."
GILD closed at $49.31 a share yesterday.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in